NCT06040320View on ClinicalTrials.gov

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 4, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2031

Conditions
Post-transplant Lymphoproliferative Disorder
Interventions
DRUG

Polatuzumab vedotin

Given at 1.8 mg/kg

DRUG

Rituximab

Given at 375 mg/m\^2

DRUG

CHP

Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER